Differential anti-inflammatory effects of immunosuppressive drugs: Cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production

Inflammation Research

Volumn 49, Issue 1, 2000, Pages 20-26

  Attur, M G ^a   Patel, R ^a   Thakker, G ^b   Vyas, P ^c   Levartovsky, D ^d   Patel, P ^a   Naqvi, S ^a   Raza, R ^a   Patel, K ^a   Abramson, D ^a   Bruno, G ^a   Abramson, S B ^a,e   Amin, A R ^a,e  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c M S UNIVERSITY OF BARODA   (India)

^d New York University Medical Center ^*  (Israel)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

COX 2; Cyclosporin; FK 506; iNOS; Rapamycin

Indexed keywords

CALCINEURIN; CYCLOOXYGENASE 2; CYCLOPHILIN; CYCLOSPORIN; HYDROCORTISONE; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; MACROPHAGE; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION;

EID: 0033983617     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000199     Document Type: Article

References (68)

1. [1] Mason J. Pharmacology of cyclosporin (sandimmune). VII. Pathophysiology and toxicology of cyclosporin in humans and animals. Pharmacol Rev 1990; 41: 423-34.
2. [2] Smith SR, Terminelli C, Kenworthy-Bott L, Phillips DL. A study of cytokine production in acute graft-vs-host disease. Cell Immunol 1991; 134: 336-48.
3. [3] Yonish-Rouach E, Fischer DG, Rubinstein M. Cyclosporin A regulates the expression of HLA-DR on human monocytes by two different mechanisms. Cell Immunol 1991; 134: 402-13.
4. [4] Wright B, Greig R, Poste G. Inhibition of macrophage activation and tumor cell cytolysis by cyclosporin-A. Biochem Biophys Res Commun 1984; 123: 710-5.
5. [5] Chiara MD, Bedoya F, Sobrino F. Cyclosporin A inhibits phorbol ester-induced activation of Superoxide production in resident mouse peritoneal macrophages. Biochem J 1989; 264: 21-6.
6. 2+ fluxes. J Immunol 1990; 144: 2659-664.
7. [7] Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998; 41: 1141-51.
8. [8] Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997; 100: 2417-23.
9. [9] Bombardier S, Cattani P, Giabattoni G, Di Munno O, Paero G, Patron C, et al. The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and non-steroidal anti-inflammatory drugs. Br J Pharmacol 1981; 73: 893-901.
10. [10] Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson AW. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol 1984; 2: 335-57.
11. [11] Davies P, MacIntyre DE. Prostaglandins and inflammation. In inflammation: Basic principles and clinical correlates. In: Gallin JI, Goldstein IM, Snyderman R, editors. New York: Raven Press, 1992: 123.
12. [12] Robinson DR, Tashjian AH, Levine L. Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis. J Clin Invest 1975; 56: 1181-88.
13. [13] Burch RM, White MF, Connor JRI. Interleukin 1 stimulates prostaglandin synthesis and cyclic AMP accumulation in Swiss 3T3 fibroblasts: interactions between two second messenger systems. J Cell Physiol 1989; 139: 29-33.
14. [14] Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res 1996; 15: 869-75.
15. [15] Narko K, Ristimäki A, MacPhee M, Smith E, Haudenschild CC, Hla T. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J Biol Chem 1997; 272: 21455-60.
16. [16] Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin enoperoxide synthase 2. Cell 1995; 83: 493-501.
17. [17] Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-40.
18. [18] Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
19. [19] Gilliam MB, Sherman MP, Griscavage JM, Ignarro LJ. A spectrophotometric assay for nitrate using NADPH oxidation by Aspergillus nitrate reductase. Anal Biochem 1993; 212: 359-65.
20. [20] Amin AR, Attur MG, Patel RN, Thakker GD, Marshall PJ, Rediske J, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: Influence of nitric oxide. J Clin Invest 1997; 99: 1231-37.
21. [21] Amin AR, Vyas P, Attur MG, Leszczynska-Piziak J, Patel R, Weissman G, et al. The mode of action of aspirin-like drugs: Effect on inducibles nitric oxide synthase. Proc Natl Acad Sci USA 1995; 92: 7926-30.
22. [22] Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
23. [23] Vane JR, Mitchell J, Appleton I, Tomlinson A, Bishopbailey D, Croxtall J, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046-50.
24. [24] Amin AR, Attur MG, Thakker GD, Patel PD, Vyas P, Patel RN, et al. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996; 93: 14014-19.
25. [25] Langford CA, Klippel JH, Balow JE, James SP, Sneller MC. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part I: rheumatologic and renal diseases. Ann Intern Med 1998; 128: 1021-28.
26. [26] Taylor AC, Connell WR, Elliot R, d'Apice AJ. Oral cyclosporin in refractory inflammatory bowel disease. Aust N Z J Med 1998; 28; 179-83.
27. [27] Thali M. Cyclosporins; immunosuppressive drugs with anti-HIV-1 activity. Mol Med Today 1995; 1; 2878-91.
28. [28] Billiar TR. Nitric oxide: Novel biology with clinical relevance. Ann Surg 1995; 221: 339-49.
29. [29] Vane JR, BakhLe VS., Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
30. 2 production by nitric oxide in activated murine macrophages. J Immunol 1999; 162: 4191-97.
31. [31] Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994; 269: 13725-28.
32. [32] Wu KK. Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 1995; 33: 179-201.
33. [33] Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Nelson N, et al. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240-4.
34. [34] Nashan B, Bleck J, Wonigeit K, Vogt P, Christians U, Sewin KF, et al. Effect of the application form of cyclosporine on blood levels, comparison of oral solution and capsules. Transplant Proc 1988; 20: 637-39.
35. [35] Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483-510.
36. [36] Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519-60.
37. [37] Akita K, Dusting GJ, Hickey H. Suppression of nitric oxide production by cyclosporin A and FK506A in rat vascular smooth muscle cells. Clin Exp Pharmacol 1994; 21: 231-33.
38. [38] Muhl H, Kunz D, Rob P, Pfeilschifter J. Cyclosporin derivatives inhibit interleukin 1beta induction of nitric oxide synthase in renal mesangial cells. Eur J Pharmacol 1993; 249: 95-100.
39. [39] Fast DJ, Lynch RC Leu RW. Cyclosporin A inhibts nitric oxide production by L929 cells in response to tumor necrosis factor and interferon-γ. J Interferon Res 1993; 13: 235-40.
40. [40] Benson A, Ziegler HJ. Macrophages as targets for inhibition by cyclosporine. Transplantation 1988; 47: 696-703.
41. [41] Hattori V, Nakanishi N. Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages. Cell Immunol 1995; 165: 7-11.
42. [42] Marumo T, Nakaki T, Hishikawa K, Suzuki H, Kato R, Saruta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 1995; 25: 764-68.
43. [43] Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA 1993; 90: 9808-12.
44. [44] Edwin SS, Branch DW, Scott JR, Silver RM, Mitchell MD. Cyclosporin A attenuates increased prostaglandin and thromboxane production in response to various stimuli in human decidua. Am J Reproid Immunol 1993; 30: 154-59.
45. 2 production by fetal amnion cells in response to various stimuli. Prostaglandins 1996; 52: 51-61.
46. [46] Martin M, Neumann D, Hoff T, Resch K, DeWitt DL, Goppelt-Struebe M. Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 1994; 45: 150-58.
47. [47] Radeke HH, Kuster S, Kaever V, Resch K. Effects of cyclosporin and FK-506 on glomerular mesangial cells. Evidence for direct inhibition of thromboxane synthase by low cyclosporin concentrations. Eur J Clin Pharmacol 1993; 44: S11-S16.
48. [48] Habib A, Bernard C, Lebret M, Créminon C, Esposito B, Tedgui A, et al. Regulation of the expression of cyclooxygenase-2 by nitric oxide in rat peritoneal macrophages. J Immunol 1997; 158: 3845-51.
49. [49] Stadler J, Harbrecht BG, Di Silvio M, Curran RD, Jordan ML, Simmons RL, et al. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat kupffer cells. J Leukocyte Biol 1997; 53: 165-72.
50. [50] Swierkosz TA, Mitchell J, Warner TD, Botting RM, Vane JR. Coinduction of nitric oxide synthase and cyclo-oxygenase: inter-actions between nitric oxide and prostanoids. Br J Pharmacol 1995; 114; 1335-42.
51. 2 production independent of its effect on nitric oxide. J Immunol 1999; 162: 3160-67.
52. [52] Badger AM, Cook MN, Lark MW, Newman-Tarr TM, Swift BA, Nelson AH, et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998; 161: 467-73.
53. TM (SB 203508) in murine macrophages and bovine chondrocytes stimulated with LPS. Inflamm Res 1999; 48: 337-43.
54. [54] Amin AR, Patel RN, Thakker GD, Lowenstein CJ, Attur MG, Abramson SB. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycyclines and chemically modified tetracyclines. FEBS Lett 1997; 410: 259-64.
55. [55] Ristimäki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 1996; 318: 325-31.
56. [56] Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan, C. Mechanisms of suppression of macrophage nitric-oxide release by transforming growth-factor-beta. J Exp Med 1993; 178: 605-13.
57. [57] Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-34.
58. [58] Nair APK, Hahn S, Banholzer R, Hirch HH, Moroni C. Cyclosporin a inhibits growth of automne tumour cell lines by destabilizing interleukin-3 mRNA. Nature 1994; 369: 239-42.
59. [59] Burkart V, Imai Y, Kallmann B, Kolb H. Cyclosporin A protects pancreatic islet cells from nitric oxide-dependent macrophage cytotoxicity. FEBS Lett 1992; 313: 56-58.
60. [60] Funder JW. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med 1997; 48: 231-40.
61. [61] Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Colch) 1998; 94: 557-72.
62. [62] Bobadilla NA, Gamba G, Tapia E, Garcia-Torres R, Bolio A, Lopez-Zetina P, et al. Role of NO in cyclosporin nephrotoxicity: effects of chronic NO inhibition and NO synthases gene expression. Am J Physiol 1998; 274: F791-98.
63. [63] Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998; 30: 1573-79.
64. [64] Langford CA, Klippel JH, Balow JE, James SP, Sneller MC. Use of cytotoxic agents and cyclosporine in the treatment of auto-immune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 1998; 129: 49-58.
65. [65] Meijssen MA. Cyclosporine and inflammatory bowel disease: buying time. Mediators Inflamm 1998; 7: 145-7.
66. [66] Hutcheson AE, Rao MR, Olinde KD, Markov AK. Myocardial toxicity of cyclosporin A: inhibition of calcium ATPase and nitric oxide synthase activities and attenuation by fructose-1,6-diphosphate in vitro. Res Commun Mol Pathol Pharmacol 1995; 89: 17-26.
67. [67] Yocum D. Cyclosporine and other experimental immunomodulatory agents. Amer College for Rheumatology. Clinical Symposia Special Lectures. Medical Aspects Lectures, 1997.
68. [68] MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-50.